This work was undertaken following the finding that PMN-MDSCs devoid of SIRPα in patients with metastatic melanoma demonstrated a strong capacity to kill T cells using trogocytosis and production of ROS, without in vitro activation (26). Here, SIRPA is linked to metastatic melanoma.